Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

AbbVie remains well-positioned for long-term growth, despite recent share price consolidation and near-term geopolitical headwinds. I expect Skyrizi and Rinvoq to drive double-digit revenue growth in 2026 and ahead of the company's initial guidance. With Humira erosion largely in the rearview mirror, I anticipate accelerating dividend increases and increased business development activity as the previous acquisitions are digested.

Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact areas in psoriasis and long-term treatment of psoriatic arthritis Data includes real-world evidence of minimal disease activity and clinical long-term safety outcomes of upadacitinib in atopic dermatitis, as well as investigational Phase 3 data for vitiligo and alopecia areata NORTH CHICAGO, Ill., March 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado.

AbbVie has increased its dividend by more than 330% since 2013. It has a robust pipeline of drugs in development and growing revenue, too.

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

LLY's obesity drugs fuel explosive growth, while ABBV depends on Skyrizi and Rinvoq. Let's see which drugmaker has the stronger 2026 outlook.

Partnership expands "Striking Out Cancer" campaign beginning on Opening Day AbbVie named Official Pharmaceutical Partner of Major League Baseball (MLB), expanding Striking Out Cancer league-wide starting on Opening Day Each strikeout will trigger a donation from AbbVie to support Stand Up To Cancer Integrated across every game and key MLB events, Striking Out Cancer transforms baseball's most iconic moments into season-long national impact NORTH CHICAGO, Ill., March 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a multi-year partnership with Major League Baseball (MLB), naming AbbVie the Official Pharmaceutical Partner of MLB beginning with the 2026 season.

Both companies have distributions boasting above-average yields. One is even a Dividend King.